标题/作者	年份
Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England Journal of Medicine 383 (7), 617-629	2020
Targeting apoptosis in cancer therapy BA Carneiro, WS El-Deiry Nature reviews Clinical oncology 17 (7), 395-417	2020
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges RM Shallis, R Wang, A Davidoff, X Ma, AM Zeidan Blood reviews 36, 70-87	2019
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial AH Wei, P Montesinos, V Ivanov, CD DiNardo, J Novak, K Laribi, I Kim, ... Blood, The Journal of the American Society of Hematology 135 (24), 2137-2145	2020
Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives L Zhong, Y Li, L Xiong, W Wang, M Wu, T Yuan, W Yang, C Tian, Z Miao, ... Signal transduction and targeted therapy 6 (1), 201	2021
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN H Döhner, AH Wei, FR Appelbaum, C Craddock, CD DiNardo, H Dombret, ... Blood, The Journal of the American Society of Hematology 140 (12), 1345-1377	2022
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803	2020
Epigenetic therapy in immune-oncology PA Jones, H Ohtani, A Chakravarthy, DD De Carvalho Nature Reviews Cancer 19 (3), 151-161	2019
Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology MS Tallman, ES Wang, JK Altman, FR Appelbaum, VR Bhatt, D Bixby, ... Journal of the National Comprehensive Cancer Network 17 (6), 721-749	2019
Myelodysplastic syndromes M Cazzola New England Journal of Medicine 383 (14), 1358-1374	2020
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ... Blood, The Journal of the American Society of Hematology 135 (7), 463-471	2020
Acute myeloid leukemia: current progress and future directions H Kantarjian, T Kadia, C DiNardo, N Daver, G Borthakur, E Jabbour, ... Blood cancer journal 11 (2), 41	2021
Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes DA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, ... Journal of clinical oncology 39 (14), 1584	2021
Small molecules, big impact: 20 years of targeted therapy in oncology PL Bedard, DM Hyman, MS Davids, LL Siu The Lancet 395 (10229), 1078-1088	2020
Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia S Pei, DA Pollyea, A Gustafson, BM Stevens, M Minhajuddin, R Fu, ... Cancer discovery 10 (4), 536-551	2020
Advances in the treatment of acute myeloid leukemia: new drugs and new challenges NJ Short, M Konopleva, TM Kadia, G Borthakur, F Ravandi, CD DiNardo, ... Cancer discovery 10 (4), 506-525	2020
Clinical and therapeutic implications of cancer stem cells MF Clarke New England Journal of Medicine 380 (23), 2237-2245	2019
How I treat acute myeloid leukemia in the era of new drugs CD DiNardo, AH Wei Blood, The Journal of the American Society of Hematology 135 (2), 85-96	2020
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ... Cancer discovery 9 (7), 910-925	2019
Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies MP Chao, CH Takimoto, DD Feng, K McKenna, P Gip, J Liu, JP Volkmer, ... Frontiers in oncology 9, 1380	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。